medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2010, Número 2

<< Anterior Siguiente >>

Rev Invest Clin 2010; 62 (2)


Guía clínica para el manejo farmacológico de la presión arterial en pacientes con enfermedad vascular cerebral después de la fase aguda

Murillo-Bonilla L, Lepe-Cameros L, Espinoza-Casillas C, Leyva-Rendón A, López M, León-Jiménez C, Enríquez-Coronel G, Arauz A, Cantú C, Lizola-Hernández J, Méndez-González C, Ruíz-Sandoval JL, Merino JG, Romano J, Barinagarrementeria F, Villarreal-Careaga J

Idioma: Español
Referencias bibliográficas: 32
Paginas: 152-161
Archivo PDF: 111.06 Kb.


FRAGMENTO

La hipertensión arterial (HTA) con una prevalencia mundial de mil millones de personas es, sin lugar a duda, el factor de riesgo vascular de mayor importancia. El riesgo acumulado de desarrollar HTA se eleva a partir de los 55 años de edad, llegando a cifras de 90% conforme envejece la población.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar C, Cravioto P, et al. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. Cuernavaca, Mor. Instituto Nacional de Salud Pública; 2003.

  2. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando-Hernández S, Hernández-Avila M, Sepúlveda- Amor J. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública; 2006.

  3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-52.

  4. He FJ, MacGregor GA. Efecto de la reducción moderada de sal a largo plazo en la presión arterial (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http:// www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).

  5. World Health Report 2002: Reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization, 2002. http://www.who.int/whr/2002.

  6. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: A cohort study. Lancet 2001; 358: 1682-6.

  7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Agespecific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002; 360: 1903-13.

  8. MacMahon S, Peto R, Collins R, Godwin J, MacMahon S, Cuttler J, Sorlie P, et al. Blood pressure, stroke, and coronary heart disease. Lancet 1990; 335: 765-74.

  9. Law MR, Morris JK, Wald JN. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective studies. BMJ 2009; 338: 1245-61.

  10. Amar J, Cambou JP, Touzé E, Bongard V, Jullien G, Vahanian A, et al. Comparison of hypertension management after stroke and myocardial infarction: results from ECLAT1 – a French Nationwide Study. Stroke 2004; 35: 1579-83.

  11. Fahey T, Schroeder K, Ebrahim S. Intervenciones para mejorar el control de la presión arterial en pacientes hipertensos (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com.

  12. Rashid P, Leonardi-Bee J, Bath Ph. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34: 2741-8.

  13. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the Health Survey for England 1994. J Hypertens 1998; 16: 747-53.

  14. Hansson L, Himmelman A. Combination therapy in the treatment of hypetension. In: Swales JD, ed. Textbook of hypertension. London: Blackwell Scientific Publications; 1994, p. 1142-9.

  15. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with n antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

  16. Lindholm LH, Carlberg B, Samvelsson. Should b blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-53.

  17. The heart outcomes prevention evaluation study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.

  18. PROGRESS Collaborative Group. Randomised trial of a perindopril- based blood-pressure-lowering regimen among 6105 individuals with previous troke or transient ischaemic attack. Lancet 2001; 358: 1033-41.

  19. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and mortality after stroke, Eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-24.

  20. Yusuf S, Phil D, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225-37.

  21. Ovbiagele B, Hills NK, Saver JL, Johnston SC, for the CASPR investigators. Antihypertensive medications prescribed at discharge after an acute ischemic cerebrovascular event. Stroke 2005; 36: 1944-7.

  22. Paul SL, Thrift AG. Control of hypetension 5 years after stroke in the North East Melbourne Stroke Incidence Study. Hypertension 2006; 48: 260-5.

  23. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart association. Professional education committee of the council for high blood pressure research. Hypertension 2008; 51: 1403-19.

  24. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.

  25. Lloyd-Jones DM, Evans JC, Larson MG, O´Donell CJ, Rocella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36: 594-9.

  26. Hansson L, Hedner T, Ludn-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonist compared with diuretics and b-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.

  27. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003; 289: 2073-82.

  28. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

  29. Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan vs atenolol: The losartan for endpoint reduction in hypertension study. Hypertension 2005; 45: 46-52.

  30. The Scottish Intercollegiate Guidelines Network. Management of stable angina. A national clinical guideline. The Scottish Intercollegiate Guidelines Network, February 2007, No. 96. Disponible en: http://www.sign.ac.uk/pdf/sign96.pdf

  31. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a noncalcium antagnonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (INVEST). A randomized controlled trial. JAMA 2003; 290: 2805-16.

  32. Dahlöf B, Sever P, Poulter N, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with and antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumetiazida as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.




2020     |     www.medigraphic.com